Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

627 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Incidence and risk factors of central nervous system recurrence in aggressive lymphoma--a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL).
Boehme V, Zeynalova S, Kloess M, Loeffler M, Kaiser U, Pfreundschuh M, Schmitz N. Boehme V, et al. Among authors: kaiser u. Ann Oncol. 2007 Jan;18(1):149-157. doi: 10.1093/annonc/mdl327. Epub 2006 Oct 3. Ann Oncol. 2007. PMID: 17018708 Free article. Clinical Trial.
Mantle-cell lymphomas have more widespread disease and a slower response to chemotherapy compared with follicle-center lymphomas: results of a prospective comparative analysis of the German Low-Grade Lymphoma Study Group.
Hiddemann W, Unterhalt M, Herrmann R, Wöltjen HH, Kreuser ED, Trümper L, Reuss-Borst M, Terhardt-Kasten E, Busch M, Neubauer A, Kaiser U, Hanrath RD, Middeke H, Helm G, Freund M, Stein H, Tiemann M, Parwaresch R. Hiddemann W, et al. Among authors: kaiser u. J Clin Oncol. 1998 May;16(5):1922-30. doi: 10.1200/JCO.1998.16.5.1922. J Clin Oncol. 1998. PMID: 9586911 Clinical Trial.
Randomized study to evaluate the use of high-dose therapy as part of primary treatment for "aggressive" lymphoma.
Kaiser U, Uebelacker I, Abel U, Birkmann J, Trümper L, Schmalenberg H, Karakas T, Metzner B, Hossfeld DK, Bischoff HG, Franke A, Reiser M, Müller P, Mantovani L, Grundeis M, Rothmann F, von Seydewitz CU, Mesters RM, Steinhauer EU, Krahl D, Schumacher K, Kneba M, Baudis M, Schmitz N, Pfab R, Köppler H, Parwaresch R, Pfreundschuh M, Havemann K. Kaiser U, et al. J Clin Oncol. 2002 Nov 15;20(22):4413-9. doi: 10.1200/JCO.2002.07.075. J Clin Oncol. 2002. PMID: 12431962 Clinical Trial.
Sequential high dose chemotherapy as initial treatment for aggressive sub-types of non-Hodgkin lymphoma: results of the international randomized phase III trial (MISTRAL).
Betticher DC, Martinelli G, Radford JA, Kaufmann M, Dyer MJ, Kaiser U, Aulitzky WE, Beck J, von Rohr A, Kovascovics T, Cogliatti SB, Cina S, Maibach R, Cerny T, Linch DC. Betticher DC, et al. Among authors: kaiser u. Ann Oncol. 2006 Oct;17(10):1546-52. doi: 10.1093/annonc/mdl153. Epub 2006 Aug 3. Ann Oncol. 2006. PMID: 16888080 Free article. Clinical Trial.
Dexamethasone, high-dose cytarabine, and cisplatin in combination with rituximab as salvage treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma.
Mey UJ, Orlopp KS, Flieger D, Strehl JW, Ho AD, Hensel M, Bopp C, Gorschlüter M, Wilhelm M, Birkmann J, Kaiser U, Neubauer A, Florschütz A, Rabe C, Hahn C, Glasmacher AG, Schmidt-Wolf IG. Mey UJ, et al. Among authors: kaiser u. Cancer Invest. 2006 Oct;24(6):593-600. doi: 10.1080/07357900600814490. Cancer Invest. 2006. PMID: 16982464 Clinical Trial.
High-dose chemotherapy with autologous stem cell support in first-line treatment of aggressive non-Hodgkin lymphoma - results of a comprehensive meta-analysis.
Greb A, Bohlius J, Trelle S, Schiefer D, De Souza CA, Gisselbrecht C, Intragumtornchai T, Kaiser U, Kluin-Nelemans HC, Martelli M, Milpied NJ, Santini G, Verdonck LF, Vitolo U, Schwarzer G, Engert A. Greb A, et al. Among authors: kaiser u. Cancer Treat Rev. 2007 Jun;33(4):338-46. doi: 10.1016/j.ctrv.2007.02.002. Epub 2007 Apr 2. Cancer Treat Rev. 2007. PMID: 17400393
CNS disease in younger patients with aggressive B-cell lymphoma: an analysis of patients treated on the Mabthera International Trial and trials of the German High-Grade Non-Hodgkin Lymphoma Study Group.
Schmitz N, Zeynalova S, Glass B, Kaiser U, Cavallin-Stahl E, Wolf M, Haenel M, Loeffler M, Truemper L, Pfreundschuh M. Schmitz N, et al. Among authors: kaiser u. Ann Oncol. 2012 May;23(5):1267-1273. doi: 10.1093/annonc/mdr440. Epub 2011 Oct 11. Ann Oncol. 2012. PMID: 21989328 Free article.
Significant dose Escalation of Idarubicin in the treatment of aggressive Non- Hodgkin Lymphoma leads to increased hematotoxicity without improvement in efficacy in comparison to standard CHOEP-14: 9-year follow up results of the CIVEP trial of the DSHNHL.
Hohloch K, Zwick C, Ziepert M, Hasenclever D, Kaiser U, Engert A, Höffkes HG, Kroschinsky F, Mesters R, Feller AC, Löffler M, Trümper L, Pfreundschuh M; German High-Grade Non-Hodgkin´s Lymphoma Study Group (DSHNHL). Hohloch K, et al. Among authors: kaiser u. Springerplus. 2014 Jan 3;3:5. doi: 10.1186/2193-1801-3-5. eCollection 2014 Jan 3. Springerplus. 2014. PMID: 24455463 Free PMC article.
627 results